We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+0.65%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$73.9B
AUM Growth
-$2.32B
(-3%)
Cap. Flow
-$2.03B
Cap. Flow
% of AUM
-2.75%
Top 10 Holdings %
Top 10 Hldgs %
22.54%
Holding
3,088
New
92
Increased
1,359
Reduced
1,564
Closed
46
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$60.7M |
| 2 |
Analog Devices
ADI
|
+$46.1M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$37.3M |
| 4 |
Match Group
MTCH
|
+$28.2M |
| 5 |
GXO Logistics
GXO
|
+$19.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$89.3M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$78.9M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$77.4M |
| 4 |
Apple
AAPL
|
+$77M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$70.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.91% |
| 2 | Financials | 14.2% |
| 3 | Healthcare | 13.07% |
| 4 | Consumer Discretionary | 12.09% |
| 5 | Communication Services | 9.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2701
Alignment Healthcare
ALHC
$2.98B
| $348K | ﹤0.01% |
21,787
+1,225
| +6% | +$23.7K |
|
2702
NVE Corp
NVEC
$609M
| $347K | ﹤0.01% |
5,425
+152
| +3% | +$10.8K |
|
2703
Tiptree Inc
TIPT
$675M
| $347K | ﹤0.01% |
34,611
+468
| +1% | +$4.58K |
|
2704
Transcat
TRNS
$871M
| $347K | ﹤0.01% |
5,387
+763
| +17% | +$48.7K |
|
2705
CytomX Therapeutics
CTMX
$754M
| $346K | ﹤0.01% |
67,933
+3,757
| +6% | +$20.1K |
|
|
KZR
2706
DELISTED
Kezar Life Sciences
KZR
| $345K | ﹤0.01% |
3,993
+108
| +3% | +$7.15K |
|
|
XXII
2707
22nd Century Group
XXII
$1.48M
| – | – |
0
| – | – |
|
|
AGTI
2708
DELISTED
Agiliti Inc
AGTI
| $344K | ﹤0.01% |
18,059
+1,070
| +6% | +$21.5K |
|
2709
Alibaba
BABA
$308B
| $342K | ﹤0.01% |
+2,310
| New | +$420K |
|
|
ITIC
2710
Investors Title Co
ITIC
$547M
| $342K | ﹤0.01% |
1,873
-12
| -0.6% | -$2.16K |
|
2711
EverQuote
EVER
$906M
| $341K | ﹤0.01% |
18,324
+875
| +5% | +$20.9K |
|
2712
Lifetime Brands
LCUT
$211M
| $340K | ﹤0.01% |
18,698
+730
| +4% | +$12.2K |
|
2713
Rafael Holdings
RFL
$107M
| $340K | ﹤0.01% |
11,220
+225
| +2% | +$10.3K |
|
|
SEI
2714
Solaris Energy Infrastructure
SEI
$3.82B
| $340K | ﹤0.01% |
40,809
+254
| +0.6% | +$2.06K |
|
2715
Limoneira
LMNR
$251M
| $337K | ﹤0.01% |
20,828
-9
| -0% | -$151 |
|
2716
Avita Medical
RCEL
$240M
| $337K | ﹤0.01% |
19,007
+1,096
| +6% | +$20.7K |
|
2717
NWPX Infrastructure Inc
NWPX
$1.15B
| $336K | ﹤0.01% |
14,185
+276
| +2% | +$7.3K |
|
|
SIEN
2718
DELISTED
Sientra, Inc.
SIEN
| $336K | ﹤0.01% |
5,871
+181
| +3% | +$12.4K |
|
|
SCWX
2719
DELISTED
SecureWorks Corp Class A Common Stock
SCWX
| $335K | ﹤0.01% |
16,874
+700
| +4% | +$14.5K |
|
|
LBC
2720
DELISTED
Luther Burbank Corporation Common Stock
LBC
| $334K | ﹤0.01% |
24,873
+750
| +3% | +$9.55K |
|
|
ATNX
2721
DELISTED
Athenex, Inc. Common Stock
ATNX
| $334K | ﹤0.01% |
5,552
-210
| -4% | -$15.3K |
|
2722
BioAtla
BCAB
$5.74M
| $333K | ﹤0.01% |
227
+17
| +8% | +$33.1K |
|
2723
Cogent Biosciences
COGT
$7.24B
| $333K | ﹤0.01% |
39,595
+1,315
| +3% | +$10.1K |
|
|
KALV
2724
DELISTED
KalVista Pharmaceuticals
KALV
| $333K | ﹤0.01% |
19,061
+897
| +5% | +$18.2K |
|
2725
Cytosorbents Corp
CTSO
$22.6M
| $332K | ﹤0.01% |
40,852
+425
| +1% | +$3.45K |
|
Similar funds
VAM
RhumbLine Advisers's Q3 2021 Portfolio in Review
As of Q3 2021, RhumbLine Advisers held 3,088 positions worth $73.9B, down 3% from $76.2B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Trading was light in Q3 2021: portfolio turnover was 4.5%. RhumbLine Advisers opened 92 new positions and exited 46, leaving the 3,088-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 23% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q3 2021 buy was GXO Logistics: 250,722 shares worth $19.7M.
- RhumbLine Advisers added most to Moderna in Q3 2021, an estimated $60.7M increase.
- RhumbLine Advisers's biggest Q3 2021 reduction was Microsoft, cutting an estimated $89.3M.
- RhumbLine Advisers fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $77.4M.
- RhumbLine Advisers's ten largest holdings make up 23% of its $73.9B portfolio in Q3 2021.
- RhumbLine Advisers opened 92 new positions and closed 46 in Q3 2021.
- RhumbLine Advisers's portfolio value fell 3% quarter-over-quarter to $73.9B.
Based on RhumbLine Advisers's 13F filing for Q3 2021, filed 12 Nov 2021.